PMID- 24455227
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140123
LR  - 20211021
IS  - 2090-1364 (Print)
IS  - 2090-1372 (Electronic)
IS  - 2090-1364 (Linking)
VI  - 2013
DP  - 2013
TI  - Transforming Growth Factor- beta 1 Gene Polymorphism (T29C) in Egyptian Patients 
      with Hepatitis B Virus Infection: A Preliminary Study.
PG  - 293274
LID - 10.1155/2013/293274 [doi]
LID - 293274
AB  - The interindividual variations in the capacity of transforming growth factor- beta 1 
      (TGF- beta 1) production have been ascribed to genetic polymorphisms in TGF- beta 1 
      gene. As pathogenesis of HBV has a genetic background, this preliminary study was 
      designed to assess the impact of TGF- beta 1 (T29C) on the susceptibility of 
      Egyptians to HBV infection. Genotyping was performed using single stranded 
      polymorphism-polymerase chain reaction (SSP-PCR) in 65 Egyptian hepatitis B 
      patients and 50 healthy controls. TGF- beta 1 plasma levels were measured using 
      Enzyme-linked immunosorbent assay (ELISA). The frequency of CC genotype was 
      significantly higher (P < 0.05) in HBV patients compared to controls. On the 
      contrary, TC genotype did not show significant difference in both groups. TT 
      genotype was significantly higher (P < 0.01) in controls than HBV patients. Our 
      current preliminary data revealed that the frequency of the genotypes in the 
      controls were within Hardy-Weinberg equilibrium (HWE) while the patients group 
      was out of HWE (P < 0.01). TGF- beta 1 was significantly (r = -0.684; P < 0.001) 
      deceased in the sera of patients as compared to normal subjects. Depending on our 
      preliminary work, CC genotype may act as a host genetic factor in the 
      susceptibility to HBV infection in Egyptians. Taken together, the current data 
      pointed to the importance of polymorphism of TGF- beta 1 gene (T29C) in HBV 
      infection.
FAU - Talaat, Roba M
AU  - Talaat RM
AD  - Molecular Biology Department, Genetic Engineering and Biotechnology Research 
      Institute (GEBRI), University of Sadat City, Sadat City 22857, Egypt.
FAU - Dondeti, Mahmoud F
AU  - Dondeti MF
AD  - Molecular Biology Department, Genetic Engineering and Biotechnology Research 
      Institute (GEBRI), University of Sadat City, Sadat City 22857, Egypt.
FAU - El-Shenawy, Soha Z
AU  - El-Shenawy SZ
AD  - Biochemistry Department, National Liver Institute (NLI), Menoufiya University, 
      Shebeen El-Kom, Menoufiya 32511, Egypt.
FAU - Khamiss, Omaima A
AU  - Khamiss OA
AD  - Animal Biotechnology Department, Genetic Engineering and Biotechnology Research 
      Institute (GEBRI), University of Sadat City, Sadat City 22857, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20131218
PL  - United States
TA  - Hepat Res Treat
JT  - Hepatitis research and treatment
JID - 101542600
PMC - PMC3878635
EDAT- 2014/01/24 06:00
MHDA- 2014/01/24 06:01
PMCR- 2013/12/18
CRDT- 2014/01/24 06:00
PHST- 2013/05/07 00:00 [received]
PHST- 2013/10/15 00:00 [revised]
PHST- 2013/10/29 00:00 [accepted]
PHST- 2014/01/24 06:00 [entrez]
PHST- 2014/01/24 06:00 [pubmed]
PHST- 2014/01/24 06:01 [medline]
PHST- 2013/12/18 00:00 [pmc-release]
AID - 10.1155/2013/293274 [doi]
PST - ppublish
SO  - Hepat Res Treat. 2013;2013:293274. doi: 10.1155/2013/293274. Epub 2013 Dec 18.